BTIG is a leading global financial services firm specializing in investment banking, institutional trading, research, and ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) recently announced significant developments regarding its private placement agreement. On January 28, 2025, NRx Pharmaceuticals, Inc. entered into an Amended ...

NRX Pharmaceuticals shares are moving higher on Tuesday after it invested $27 million in its subsidiary HOPE Therapeutics.

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in almost three weeks, drawing heavy ...

NRx Pharmaceuticals (NRXP) announced that it has entered into a binding agreement for a registered direct offering of its common stock with ...

Shares of NRx Pharmaceuticals stock opened at $3.14 on Tuesday. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $7.33. The stock has a market cap of $37.96 million, a P/E ...

NRXP has entered a transformative partnership with Alvogen Pharmaceuticals for the development and marketing of NRX-101.

On Friday, NRX Pharmaceuticals Inc (NRXP) stock saw a decline, ending the day at $4.01 which represents a decrease of $-0.25 or -5.87% from the prior close of $4.26. The stock opened at $4.12 and ...

迈阿密 - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP )，一家目前市值为3437万美元的临床阶段生物制药公司，宣布达成一项融资协议，以支持其子公司HOPE Therapeutics, Inc.。该公司股票目前交易价格为2.85美元，显示出显著的波动性，尽管年初至今的回报率强劲达29.55%，但目前仍远低于其52周高点7.33美元。根据 InvestingPro ...

Hope Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced engagement of BTIG, a leading global financial services ...

The Company has recently announced execution of an agreement for $27 million in funding for HOPE Clinic Acquisition. Upon closing of the first tranch ...

Ascendiant Capital Markets increased their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd.